Table 2 Univariate Cox Proportional Hazards models of pre- and post-transplantation factors predicting relapse-free survival.
Hazard ratio (95% CI for HR) | p-value | |
|---|---|---|
Pre-transplantation factors | ||
JAK2 mutation present | 1.02 (0.48–2.16) | 0.96 |
Age at transplant (>55 years vs. <55 years) | 1.39 (0.61–3.12) | 0.43 |
DIPSS stratification (high risk vs. intermediate-2) | 1.76 (0.41–7.45) | 0.45 |
JAK inhibitor therapy prior to SCT | 0.93 (0.41–2.11) | 0.86 |
Pre-HCT RBC transfusion dependence | 2.87 (1.09–7.55) | 0.03 |
Pre-HCT platelet transfusion dependence | 0.65 (0.19–2.16) | 0.49 |
High risk cytogenetics | 2.54 (1.10–5.87) | 0.03 |
Conditioning regimen (reduced intensity vs. myeloablative) | 0.74 (0.30–1.83) | 0.52 |
Graft vs. host disease prophylaxis (Calcineurin inhibitor + methotrexate vs. Calcineurin inhibitor + mycophenolate) | 0.98 (0.43–2.24) | 0.97 |
Donor source (matched related vs. other) | 0.57 (0.27–1.21) | 0.15 |
Anti-thymocyte globulin administered | 0.63 (0.29–1.37) | 0.25 |
Post-transplantation (day +100) Factors | ||
RBC transfusion dependence | 9.02 (4.00–20.35) | <0.001 |
Platelet transfusion dependence | 8.16 (3.84–17.37) | <0.001 |
100% Donor chimerism in CD3 + cells | 1.01 (0.37–2.79) | 0.98 |
100% Donor chimerism in CD33 + cells | 0.21 (0.07–0.62) | 0.004 |
Grade ≥2 bone marrow fibrosis (vs. Grade ≤1) | 2.76 (1.10–6.93) | 0.03 |
No improvement in bone marrow fibrosis | 1.52 (0.69–3.33) | 0.30 |
Acute graft vs. host disease (grades 2–4 vs. Grade 0–1) | 1.04 (0.32–3.44) | 0.95 |
Normal spleen size | 0.42 (0.19–0.94) | 0.04 |
Unfavorable molecular status | 4.4 (4.87–10.39) | <0.001 |
Poor graft function day +100 | 2.60 (1.22–5.53) | 0.01 |
